市場調查報告書

多發性硬化症市場:全球產業分析,規模,佔有率,成長,趨勢,預測(2019∼2027年)

Multiple Sclerosis Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019 - 2027

出版商 Transparency Market Research 商品編碼 920561
出版日期 內容資訊 英文 207 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
多發性硬化症市場:全球產業分析,規模,佔有率,成長,趨勢,預測(2019∼2027年) Multiple Sclerosis Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019 - 2027
出版日期: 2019年09月17日內容資訊: 英文 207 Pages
簡介

本報告提供多發性硬化症市場相關調查,彙整市場趨勢與預測,市場規模,主要加入企業,各地區趨勢相關資訊。

第1章 序論

第2章 假設和調查方法

第3章 摘要整理

第4章 市場概要

  • 簡介
  • 概要
  • 市場趨勢
    • 促進要素
    • 阻礙要素
    • 機會
  • 市場分析與預測

第5章 主要趨勢

  • 開發平台分析
  • 藥物價格/年度成本分析
  • 各主要國家罹患率
  • 銷售額分析

第6章 市場價值與預測:各類藥物

  • 簡介和定義
  • 主要調查結果/趨勢
  • 市場價值預測
    • 干擾素B
    • Sphingosine 1磷酸受體調節劑
    • 混合聚合物
    • 單株抗體
    • NF-KB抑制劑
    • 嘧啶合成抑制劑
    • 其他
  • 市場魅力度

第7章 市場價值與預測:各給藥途徑

  • 簡介和定義
  • 主要調查結果/趨勢
  • 市場價值預測
    • 注射
    • 口服
  • 市場魅力度

第8章 市場價值與預測:各流通管道

  • 簡介和定義
  • 主要調查結果/趨勢
  • 市場價值預測
    • 院內藥局
    • 零售藥局
    • 電子商務
  • 市場魅力度

第9章 市場價值與預測:各地區

  • 主要調查結果
  • 市場價值預測
    • 北美
    • 歐洲
    • 亞太地區
    • 南美
    • 中東·非洲
  • 市場魅力度

第10章 北美

第11章 歐洲

第12章 亞太地區

第13章 南美

第14章 中東·非洲

第15章 競爭環境

  • 市場佔有率分析
  • 企業簡介
目錄

Multiple Sclerosis Drugs Market - Scope of the Report

[207 Pages Report] TMR'S report on the multiple sclerosis drugs market studies the past as well as current growth trends and opportunities, to gain valuable insights of the same indicators for the said market over the forecast period of 2019 to 2027. The report provides the overall market revenue of the multiple sclerosis drugs market for the 2017-2027 period, with 2018 as the base year, and 2027 as the forecast year. The report also provides the compound annual growth rate (CAGR) for the multiple sclerosis drugs market for the 2019-2027 forecast period.

The report is prepared after an extensive research. Primary research involved bulk of the research efforts, wherein, analysts carried out interviews with industry leaders and opinion makers. Extensive secondary research involved reaching out to key players' product literature, annual reports, press releases, and relevant documents to understand the multiple sclerosis drugs market.

Secondary research also includes Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of the top-down and bottom-up approach to study the various phenomena in the multiple sclerosis drugs market.

The report includes an elaborate executive summary along with a snapshot of the growth behavior of various segments in the scope of the study. Further, the report throws light on the changing competitive dynamics in the multiple sclerosis drugs market. These indices serve as valuable tools for existing market players as well as for entities interested in participating in the multiple sclerosis drugs market.

The report delves into the competitive landscape of the multiple sclerosis drugs market. Key players operating in the multiple sclerosis drugs market are identified, and each one of them is profiled for their distinguishing business attributes. Company overview, financial standings, recent developments, and SWOTs are some of the attributes of players in the multiple sclerosis drugs market that are profiled in this report.

Key Questions Answered in the Multiple Sclerosis Drugs Market Report

How does the development of multiple sclerosis drugs provide scope of growth for the multiple sclerosis drugs market?

How are alliances and partnerships between players widening the scope of of treatment for multiple sclerosis?

What are the revenue share projections of key segments under various criteria in the multiple sclerosis drugs market over the forecast period?

Which segment is likely to register leading revenue until the end of the forecast period in 2027?

How is the evolving healthcare system in developing countries of Asia Pacific having an impact on the overall multiple sclerosis drugs market?

Multiple Sclerosis Drugs Market - Research Objectives and Research Approach

The comprehensive report on the multiple sclerosis drugs market begins with an overview of the said market, followed by the scope and objectives of this study. Following this, the report provides detailed explanation of the objectives behind this study and healthcare compliances laid down by accredited agencies in the purview of line of treatment of multiple sclerosis.

For reading comprehensibility, the report is compiled in a chapter-wise layout, with each section further divided into small sections. The entire report comprises an exhaustive collection of graphs and tables that are appropriately interspersed in the entire compilation. Pictorial representation of the actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the multiple sclerosis drugs market in terms of drug class, route of administration, distribution channel, and region. Key segments under each criteria are studied at length, and the market share for each of them at the end of 2027 provided herein. Such valuable insights enable market stakeholders in making informed business decisions for investments in the multiple sclerosis drugs market.

Table of Contents

1. Preface

  • 1.1. Market Definition and Scope
  • 1.2. Market Segmentation
  • 1.3. Key Research Objectives
  • 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary : Global Multiple Sclerosis Drugs Market

4. Market Overview

  • 4.1. Introduction
    • 4.1.1. Multiple Sclerosis Drugs Introduction
    • 4.1.2. Industry Evolution / Developments
  • 4.2. Overview
  • 4.3. Market Dynamics
    • 4.3.1. Drivers
    • 4.3.2. Restraints
    • 4.3.3. Opportunities
  • 4.4. Global Multiple Sclerosis Drugs Market Analysis and Forecast, 2017-2027
    • 4.4.1. Global Multiple Sclerosis Drugs Market Revenue Projections (US$ Mn)

5. Key Insights

  • 5.1. Global Multiple Sclerosis Market Pipeline Analysis
  • 5.2. Multiple Sclerosis Drug Prices/ Annual Cost Analysis
  • 5.3. Multiple Sclerosis Disease Prevalence by Key Countries
  • 5.4. Multiple Sclerosis Drugs Sales Analysis 2016-2018

6. Global Multiple Sclerosis Drugs Market Analysis and Forecast, by Drug Class

  • 6.1. Introduction & Definition
  • 6.2. Key Findings / Developments
  • 6.3. Global Multiple Sclerosis Drugs Market Value Forecast, by Drug Class, 2017-2027
    • 6.3.1. Interferon-B
    • 6.3.2. Sphingosine 1 Phosphate Receptor Modulators
    • 6.3.3. Mixed Polymers
    • 6.3.4. Monoclonal Antibodies
    • 6.3.5. NF-KB Inhibitors
    • 6.3.6. Pyrimidine synthesis Inhibitors
    • 6.3.7. Others
  • 6.4. Global Multiple Sclerosis Drugs Market Attractiveness, by Drug Class

7. Global Multiple Sclerosis Drugs Market Analysis and Forecast, by Route of Administration

  • 7.1. Introduction & Definition
  • 7.2. Key Findings / Developments
  • 7.3. Global Multiple Sclerosis Drugs Market Value Forecast, by Route of Administration, 2017-2027
    • 7.3.1. Injectable
    • 7.3.2. Oral
  • 7.4. Global Multiple Sclerosis Drugs Market Attractiveness, by Route of Administration

8. Global Multiple Sclerosis Drugs Market Analysis and Forecast, by Distribution Channel

  • 8.1. Introduction & Definition
  • 8.2. Key Findings / Developments
  • 8.3. Global Multiple Sclerosis Drugs Market Value Forecast, by Distribution Channel, 2017-2027
    • 8.3.1. Hospital Pharmacies
    • 8.3.2. Retail Pharmacies
    • 8.3.3. E-commerce
  • 8.4. Global Multiple Sclerosis Drugs Market Attractiveness, by Distribution Channel

9. Global Multiple Sclerosis Drugs Market Analysis and Forecast, by Region

  • 9.1. Key Findings
  • 9.2. Global Multiple Sclerosis Drugs Market Value Forecast, by Region
    • 9.2.1. North America
    • 9.2.2. Europe
    • 9.2.3. Asia Pacific
    • 9.2.4. Latin America
    • 9.2.5. Middle East & Africa
  • 9.3. Global Multiple Sclerosis Drugs Market Attractiveness, by Region

10. North America Multiple Sclerosis Drugs Market Analysis and Forecast

  • 10.1. Introduction
    • 10.1.1. Key Findings
  • 10.2. North America Multiple Sclerosis Drugs Market Value Forecast, by Drug Class, 2017-2027
    • 10.2.1. Interferon-B
    • 10.2.2. Sphingosine 1 Phosphate Receptor Modulators
    • 10.2.3. Mixed Polymers
    • 10.2.4. Monoclonal Antibodies
    • 10.2.5. NF-KB Inhibitors
    • 10.2.6. Pyrimidine synthesis Inhibitors
    • 10.2.7. Others
  • 10.3. North America Multiple Sclerosis Drugs Market Value Forecast, by Route of Administration, 2017-2027
    • 10.3.1. Injectable
    • 10.3.2. Oral
  • 10.4. North America Multiple Sclerosis Drugs Market Value Forecast, by Distribution Channel, 2017-2027
    • 10.4.1. Hospital Pharmacies
    • 10.4.2. Retail Pharmacies
    • 10.4.3. E-commerce
  • 10.5. North America Multiple Sclerosis Drugs Market Value Forecast, by Country, 2017-2027
    • 10.5.1. U.S.
    • 10.5.2. Canada
  • 10.6. North America Multiple Sclerosis Drugs Market Attractiveness Analysis
    • 10.6.1. By Drug Class
    • 10.6.2. By Route of Administration
    • 10.6.3. By Distribution Channel
    • 10.6.4. By Country

11. Europe Multiple Sclerosis Drugs Market Analysis and Forecast

  • 11.1. Introduction
    • 11.1.1. Key Findings
  • 11.2. Europe Multiple Sclerosis Drugs Market Value Forecast, by Drug Class, 2017-2027
    • 11.2.1. Interferon-B
    • 11.2.2. Sphingosine 1 Phosphate Receptor Modulators
    • 11.2.3. Mixed Polymers
    • 11.2.4. Monoclonal Antibodies
    • 11.2.5. NF-KB Inhibitors
    • 11.2.6. Pyrimidine synthesis Inhibitors
    • 11.2.7. Others
  • 11.3. Europe Multiple Sclerosis Drugs Market Value Forecast, by Route of Administration, 2017-2027
    • 11.3.1. Injectable
    • 11.3.2. Oral
  • 11.4. Europe Multiple Sclerosis Drugs Market Value Forecast, by Distribution Channel, 2017-2027
    • 11.4.1. Hospital Pharmacies
    • 11.4.2. Retail Pharmacies
    • 11.4.3. E-commerce
  • 11.5. Europe Multiple Sclerosis Drugs Market Value Forecast, by Country/Sub-region, 2017-2027
    • 11.5.1. Germany
    • 11.5.2. U.K.
    • 11.5.3. France
    • 11.5.4. Italy
    • 11.5.5. Spain
    • 11.5.6. Rest of Europe
  • 11.6. Europe Multiple Sclerosis Drugs Market Attractiveness Analysis
    • 11.6.1. By Drug Class
    • 11.6.2. By Route of Administration
    • 11.6.3. By Distribution Channel
    • 11.6.4. By Country/Sub-region

12. Asia Pacific Multiple Sclerosis Drugs Market Analysis and Forecast

  • 12.1. Introduction
    • 12.1.1. Key Findings
  • 12.2. Asia Pacific Multiple Sclerosis Drugs Market Value Forecast, by Drug Class, 2017-2027
    • 12.2.1. Interferon-B
    • 12.2.2. Sphingosine 1 Phosphate Receptor Modulators
    • 12.2.3. Mixed Polymers
    • 12.2.4. Monoclonal Antibodies
    • 12.2.5. NF-KB Inhibitors
    • 12.2.6. Pyrimidine synthesis Inhibitors
    • 12.2.7. Others
  • 12.3. Asia Pacific Multiple Sclerosis Drugs Market Value Forecast, by Route of Administration, 2017-2027
    • 12.3.1. Injectable
    • 12.3.2. Oral
  • 12.4. Asia Pacific Multiple Sclerosis Drugs Market Value Forecast, by Distribution Channel, 2017-2027
    • 12.4.1. Hospital Pharmacies
    • 12.4.2. Retail Pharmacies
    • 12.4.3. E-commerce
  • 12.5. Asia Pacific Multiple Sclerosis Drugs Market Value Forecast, by Country/Sub-region, 2017-2027
    • 12.5.1. China
    • 12.5.2. India
    • 12.5.3. Japan
    • 12.5.4. Australia & New Zealand
    • 12.5.5. Rest of Asia Pacific
  • 12.6. Asia Pacific Multiple Sclerosis Drugs Market Attractiveness Analysis
    • 12.6.1. By Drug Class
    • 12.6.2. By Route of Administration
    • 12.6.3. By Distribution Channel
    • 12.6.4. By Country/Sub-region

13. Latin America Multiple Sclerosis Drugs Market Analysis and Forecast

  • 13.1. Introduction
    • 13.1.1. Key Findings
  • 13.2. Latin America Multiple Sclerosis Drugs Market Value Forecast, by Drug Class, 2017-2027
    • 13.2.1. Interferon-B
    • 13.2.2. Sphingosine 1 Phosphate Receptor Modulators
    • 13.2.3. Mixed Polymers
    • 13.2.4. Monoclonal Antibodies
    • 13.2.5. NF-KB Inhibitors
    • 13.2.6. Pyrimidine synthesis Inhibitors
    • 13.2.7. Others
  • 13.3. Latin America Multiple Sclerosis Drugs Market Value Forecast, by Route of Administration, 2017-2027
    • 13.3.1. Injectable
    • 13.3.2. Oral
  • 13.4. Latin America Multiple Sclerosis Drugs Market Value Forecast, by Distribution Channel, 2017-2027
    • 13.4.1. Hospital Pharmacies
    • 13.4.2. Retail Pharmacies
    • 13.4.3. E-commerce
  • 13.5. Latin America Multiple Sclerosis Drugs Market Value Forecast, by Country/Sub-region, 2017-2027
    • 13.5.1. Brazil
    • 13.5.2. Mexico
    • 13.5.3. Rest of Latin America
  • 13.6. Latin America Multiple Sclerosis Drugs Market Attractiveness Analysis
    • 13.6.1. By Drug Class
    • 13.6.2. By Route of Administration
    • 13.6.3. By Distribution Channel
    • 13.6.4. By Country/Sub-region

14. Middle East & Africa Multiple Sclerosis Drugs Market Analysis and Forecast

  • 14.1. Introduction
    • 14.1.1. Key Findings
  • 14.2. Middle East & Africa Multiple Sclerosis Drugs Market Value Forecast, by Drug Class, 2017-2027
    • 14.2.1. Interferon-B
    • 14.2.2. Sphingosine 1 Phosphate Receptor Modulators
    • 14.2.3. Mixed Polymers
    • 14.2.4. Monoclonal Antibodies
    • 14.2.5. NF-KB Inhibitors
    • 14.2.6. Pyrimidine synthesis Inhibitors
    • 14.2.7. Others
  • 14.3. Middle East & Africa Multiple Sclerosis Drugs Market Value Forecast, by Route of Administration, 2017-2027
    • 14.3.1. Injectable
    • 14.3.2. Oral
  • 14.4. Middle East & Africa Multiple Sclerosis Drugs Market Value Forecast, by Distribution Channel, 2017-2027
    • 14.4.1. Hospital Pharmacies
    • 14.4.2. Retail Pharmacies
    • 14.4.3. E-commerce
  • 14.5. Middle East & Africa Multiple Sclerosis Drugs Market Value Forecast, by Country/Sub-region, 2017-2027
    • 14.5.1. GCC Countries
    • 14.5.2. South Africa
    • 14.5.3. Rest of Middle East & Africa
  • 14.6. Middle East & Africa Multiple Sclerosis Drugs Market Attractiveness Analysis
    • 14.6.1. By Drug Class
    • 14.6.2. By Route of Administration
    • 14.6.3. By Distribution Channel
    • 14.6.4. By Country/Sub-region

15. Competition Landscape

  • 15.1. Global Multiple Sclerosis Drugs Market Share Analysis, by Company (2018)
  • 15.2. Company Profiles
    • 15.2.1. Bayer AG
    • 15.2.2. Teva Pharmaceutical Industries Ltd.
    • 15.2.3. Novartis AG
    • 15.2.4. Sanofi
    • 15.2.5. F. Hoffmann-La Roche Ltd.
    • 15.2.6. Celgene Corporation
    • 15.2.7. Acorda Therapeutics, Inc.
    • 15.2.8. Biogen Inc.
    • 15.2.9. Actelion Pharmaceuticals (Johnson & Johnson)
    • 15.2.10. EMD Serono (Merck KGaA)
Back to Top